Ignite Creation Date:
2025-12-18 @ 8:58 AM
Ignite Modification Date:
2025-12-18 @ 8:58 AM
Study NCT ID:
NCT06743776
Status:
None
Last Update Posted:
2025-11-19 00:00:00
First Post:
2024-11-20 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS
Sponsor:
None
Organization:
Study Overview
Official Title:
Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS
Status:
None
Status Verified Date:
2025-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SEANOBI-ALS
Brief Summary:
The purpose of this Expanded Access Program is to provide MN-166 (ibudilast) to ALS patients who are not eligible for an enrolling ALS clinical trial. This Expanded Access Program will assess if MN-166 can help people with ALS in slowing down the progression of the disease.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: